register

News - MedTech & Diagnostics

‘Principles and purpose tested by geopolitical complexity’, says Edwards’ APAC leader

Health Industry Hub | October 26, 2026 |

Edwards Lifesciences’ APAC leader warns that delayed diagnosis, inequitable access and the pace of technology adoption remain critical challenges for the medtech sector.

Speaking at the official opening of the Alain Cribier Innovation Training Centre in Australia, Amit Raheja, Senior Vice President of APAC at Edwards Lifesciences, said the facility is designed to bridge the gap between technological innovation and clinical implementation. It provides surgeons with hands-on training using simulated beating-heart models, allowing them to familiarise themselves with novel devices and procedures before treating patients.

“It not only allows clinicians to use the facility for their patients, but also helps to train other surgeons across the Asia Pacific region,” Raheja told Health Industry Hub.

The facility is intended to reinforce Edwards Lifesciences’ local presence, which Raheja described as a critical market for the company. Australia plays a significant role in the regional launch of the organisation’s medical technologies, with many innovations launching locally before other markets across Asia-Pacific.

For Raheja, what keeps medtech leaders up at night is the sheer diversity of the Asia-Pacific region and the nuances of patient access, regardless of geography.

“There’s so much diversity across health systems, countries and market access,” he said, pointing to the differences between established healthcare markets such as Australia, New Zealand and Korea and emerging markets including India, Thailand and Vietnam.

“Making sure that patients get served to the best capability level possible is the first thing that keeps us up,” Raheja added.

A second challenge is the substantial gap between the number of people living with structural heart disease and those receiving treatment. In Australia, approximately half a million patients suffer from heart valve disease, with around one in 20 people aged over 65 affected. Yet diagnosis remains difficult because symptoms can be mistaken for the natural effects of ageing, causing a delayed referral to cardiologists.

Raheja cited a global population of more than 20 million structural heart patients and said only around 200,000 patients are treated each year.

“It’s just a drop in the ocean of the patients that are diseased versus patients that actually get treated,” he said. “There’s a long way to go, and that’s also what keeps us up at night.”

Addressing the treatment gap requires a coordinated effort across industry, clinicians, general practitioners and the media, with greater awareness helping patients and families recognise symptoms and seek further investigation.

Despite the shortcomings, Raheja described Australia’s healthcare system as one of the better examples globally.

“One of the good things about the Australia health system is that everybody has access to healthcare,” he said. “The second thing is that through the public system the population gets access to innovative technologies relatively faster than other regional markets.”

He pointed to the United States Food and Drug Administration’s (FDA) breakthrough technology pathway as an example of how regulatory frameworks can be adapted to support earlier access to promising treatments.

“We need to adopt and look at the rest of the world on how we can get access to innovation at a much faster pace in Australia,” he said.

The pressures facing healthcare systems are compounded by geopolitical uncertainty, fiscal constraints and the growing complexity of global supply chains. Raheja acknowledged that the current environment presents significant challenges for medtech companies, but argued that patient needs must remain central to business decisions.

“The current level of geopolitical and fiscal complexity is unprecedented in the world,” he reflected. “Every industry is affected by it, including the medtech sector.”

For Edwards Lifesciences, continued investment in research and development (R&D) remains central to advancing cardiac technologies for patients who previously had limited options.

“It’s during challenging times like this where your principles and purpose truly get tested,” Raheja told Health Industry Hub.

The company’s regional manufacturing strategy is another part of its response to uncertainty. Raheja described facilities in Singapore, Costa Rica and Spain as critical to supporting continuity of care.

“By all traditional means, this can be looked at as a very expensive supply chain. But we believe this continuity is extremely important, especially in today’s world, so that we continue to serve patients,” he emphasised. “There will be complexity with geopolitical and fiscal challenges, but I think it’s the agility. It’s keeping our purpose in the front and centre of everything that we do, that allows us to treat patients.”

Ultimately, the expansion of access to structural heart technologies depends on more than the pace of innovation. For Edwards Lifesciences, the new Australian training centre represents one part of that broader effort. The more consequential challenge is ensuring that medtech advances translate into earlier intervention and better outcomes across the diverse populations of the Asia-Pacific region.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News - MedTech & Diagnostics

Roche unlocks new horizons for genomic research in Asia Pacific

Roche unlocks new horizons for genomic research in Asia Pacific

Health Industry Hub | November 9, 2026 |

Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]

More


News - Pharmaceuticals

'Unexpected and Surprising': Novartis’ Lp(a) setback raises tough questions for Amgen and Lilly - Professor Stephen Nicholls, Victorian Heart Hospital

‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly

Health Industry Hub | November 9, 2026 |

The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]

More


News - MedTech & Diagnostics

More public hospitals turn to same-day hip and knee surgery but recovery risks persist

More public hospitals turn to same-day hip and knee surgery, but key blind spots persist

Health Industry Hub | November 9, 2026 |

Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]

More


News - Pharmaceuticals

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

Health Industry Hub | November 9, 2026 |

The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]

More


This content is copyright protected. Please subscribe to gain access.